U.S. National Library of MedicineNational Institutes of Health
Skip navigation
MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You MedlinePlus Trusted Health Information for You
Contact Us FAQs Site Map About MedelinePlus
español

HealthDay Logo

Blood Pressure Drug Shows Promise for Marfan Syndrome

Losartan slowed aortic enlargement, most life-threatening defect of condition
Printer-friendly version Printer-friendly version

HealthDay

By Robert Preidt

Wednesday, June 25, 2008

HealthDay news imageWEDNESDAY, June 25 (HealthDay News) -- The high blood pressure drug losartan shows promise in treating Marfan syndrome, according to a small study by Johns Hopkins University researchers.

Marfan syndrome is a genetic disorder that affects connective tissue.

The clinical trial of 18 children with severe Marfan syndrome found that losartan slowed the enlargement of the aorta, the most life-threatening defect associated with the condition.

The patients' average rate of aortic enlargement before treatment was 3.5 millimeters in diameter per year. After treatment, it was less than half a millimeter per year.

The findings were published in the June 26 issue of the New England Journal of Medicine.

"This experience increases my belief that losartan holds great promise for treating Marfan syndrome. This would be the first therapy generated by basic research that revealed the molecular mechanism of this genetic disease," Dr. Harry Dietz, a professor in the McKusick-Nathans Institute of Genetic Medicine and director of the William S. Smilow Center for Marfan Syndrome Research at Hopkins, said in a prepared statement.

In previous research in mice with the same genetic defect that causes Marfan syndrome in humans, Dietz and colleagues found that excessive activity of the protein TGF-beta -- which is vital to cell growth and specialization -- causes many Marfan-related features.

When the mice were treated with losartan -- which is known to decrease TGF-beta activity -- the potentially deadly enlargement of the aorta was slowed or even halted.

A large, multicenter clinical trial of losartan for Marfan syndrome has been launched by the Pediatric Heart Network of the U.S. National Heart, Lung, and Blood Institute.


HealthDay

Copyright (c) 2008 ScoutNews, LLC. All rights reserved.

Related News:
More News on this Date

Related MedlinePlus Pages: